U.S. wellness spending grew 8.6% year-over-year in 2025 to $1.8 trillion, according to the Global Wellness Institute, with the sauna and bathing segment expanding at a 12% CAGR. Perspire Sauna Studio's 100th location opening this month in Scottsdale, Arizona, marks a critical density threshold for the nation's largest infrared sauna and red-light therapy franchise. The Costa Mesa-based chain has doubled its footprint since 2023, signaling that its asset-light franchise model is capturing repeat demand from health-seeking consumers at a time when preventative therapies are gaining traction.
The business sits at the intersection of two megatrends: the $87 billion global spa services market and the growing body of clinical evidence supporting photobiomodulation (PBM) for inflammation, pain, and skin health. Perspire's model combines full-spectrum infrared (IR) heat with medical-grade light-emitting diode (LED) red-light therapy (RLT) pods, a protocol that overlaps with FDA-cleared devices from companies like Joovv and PlatinumLED. While these players sell direct-to-consumer hardware, Perspire's franchise approach monetizes the recurring session-based revenue stream—akin to the membership models that powered Planet Fitness and Massage Envy.
Competitive Landscape and TAM Expansion
The infrared sauna market was valued at $1.1 billion in 2024 and is projected to reach $2.7 billion by 2032 (Grand View Research). When combined with the broader red-light therapy device market—expected to hit $11.5 billion by 2030—Perspire's integrated offering targets a dual TAM that remains fragmented. Competitors include franchise chains like SweatHouz (26 studios) and Restore Hyper Wellness (225+ locations), but the latter offers a more diversified recovery menu. Perspire's focus on IR and RLT only may give it a cost advantage in unit build-out, with initial franchise investment ranging from $269,000 to $576,000, per the company's FDD.
Investors should note that consumer-facing wellness service companies have seen mixed public-market reception. The Joint Corp. (JYNT), a chiropractic franchise, trades at 1.2x trailing revenue after a fall from its 2021 highs, while Xponential Fitness (XPOF) has faced operational controversies but continues to grow boutique studio count. Pure-play PBM device makers like Photomedex (PHMD) remain micro-cap. The franchise pipeline’s resilience in a high-rate environment could make Perspire a candidate for private equity consolidation or an eventual IPO, particularly if same-store sales continue climbing from an average of $459,000 AUV reported in its 2025 FDD.
The 100th studio is a tangible proof point that consumers are integrating light and heat therapy into their regular health routines—this is not a fad, it's a secular shift in self-care spending.
Ultimately, Perspire’s milestone is a microcosm of a larger shift: light-based therapies are moving from clinical rehab settings to mainstream wellness. For biotech investors, this consumer adoption could de-risk reimbursement pathways and accelerate payer acceptance of prescription PBM devices currently in FDA trials for diabetic neuropathy and macular degeneration. The franchise's continued unit growth will be a key real-world evidence generator for the efficacy of routine IR/RLT use, potentially expanding the end-market for a new class of therapeutic devices.
